$7.93
-0.30-3.65%
Last update: Nov 12, 4:00 PM
Atara Biotherapeutics Inc
ATRANASDAQ
Atara Biotherapeutics fell 38.5% from $13.39 to $8.23, behind the S&P 500's +12.7%. Its worst day was Jan 12 (−57.0%), and its low came Feb 20 at $4.18.
Nov 13, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Atara Biotherapeutics closed at its highest level of the year, 35.1% above where the year started.
+1.2% · S&P 500 −0.7%
Atara Biotherapeutics shares fell 57.0%, while the S&P 500 rose 0.2%.
Story events cover the past 12 months · Times ET
−57.0%, the year's worst day · S&P 500 +0.2%
Atara Biotherapeutics closed at its lowest level of the year, 68.8% below where the year started.
−1.4% · S&P 500 +0.7%
Atara Biotherapeutics shares rose 29.2%, while the S&P 500 rose 0.9%.
+29.2% · S&P 500 +0.9%
EPS of $-0.25 missed the $-0.07 estimate on $1.6M revenue (est. $1.6M).
−10.9% · S&P 500 +0.3%
EPS of $-0.29 missed the $0.32 estimate on $516,000.00 revenue (est. $2.2M).
+6.8% · S&P 500 +0.6%
EPS of $-0.32 missed the $-0.25 estimate on $630,000.00 revenue (est. $366,670.00).
−7.8% · S&P 500 +0.7%
EPS of $-0.15 beat the $-0.22 estimate on $1.2M revenue (est. $533,330.00).
+1.6% · S&P 500 +1.3%
Where it ended: a close of $8.23 on Nov 11, 2026.
Nothing in the past 12 months.
All ATRA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ATRA and SPY from Benzinga historical bars. Not investment advice.
